

Our new innovation in longevity skincare, formulated with Mitopure by Timeline, the #1 selling longevity Urolithin-A supplement, now in advanced skincare.2
Reverse your skin’s visible biological age at every life stage.3
1 Validated in partnership with Lancome’s advisory board of dermatologists, ensuring thorough review of testing protocols and results; comprehensive ingredient screening for efficacy, safety, and skin compatibility.
2Mitopure is the #1 selling Urolithin-A supplement based on latest 52-week unit sales, ending Dec 31st 2025. Absolue Longevity MD provides a topical cosmetic way to combat visible signs of aging. Does not function like Mitopure oral supplement.
3 Visible biological age defined as signs of aging such as firmness, suppleness, radiance, fine lines, smoothness, etc.
What if you could
choose your age?
[Age: 35-] Anticipate - [Age: 35-55] Intercept - [Age: 55+] Reset
Absolue Longevity MD is formulated with Mitopure® a highly pure form of Urolithin-A, a postbiotic widely recognized in the longevity field.
Anticipate [Age 35-]
Act on visible biological aging signs before they appear
Intercept [Age 35-55]
Target visible biological aging signs as they appear
Reset [Age 55+]
Reverse visible biological aging signs after they appear
*Visible biological age defined as signs of aging such as firmness, suppleness, radiance, fine lines, smoothness, etc.

A Runway Ready Collaboration
Lancôme & The Devil Wears Prada 2
Centered around the debut of our breakthrough Absolue Longevity MD collection, the collaboration brings cutting-edge skincare innovation into the cultural spotlight, both on and off screen. Woven into the fabric of the film, the collection supports the cast’s on-set beauty routines while reinforcing Lancôme’s commitment to longevity, radiance, and timeless elegance. Extending beyond traditional product placement, the partnership is seamlessly integrated into the film’s world, positioning Lancôme at the forefront of a new era where skincare meets culture.
The film debuts in theaters May 1.





